Centre Lists 34 Antimicrobials, Antivirals for Proposed Ban in Animals Under Drugs Act

Published On 2025-05-27 14:09 GMT   |   Update On 2025-05-27 14:09 GMT

New Delhi: The Central Government has issued a draft notification proposing the prohibition of import, manufacture, sale, and distribution of a total of 34 antimicrobials and their formulations for animal use, citing risks to human health.

The proposal is outlined in Gazette Notification S.O. 2298(E), dated May 22, 2025, under Section 26A of the Drugs and Cosmetics Act, 1940.

According to the notification, the government is satisfied that the use of these antimicrobials in animals “is likely to involve risk to humans,” and notes that safer veterinary alternatives are available.

The draft was published after consultation with the Drugs Technical Advisory Board (DTAB). DTAB had earlier recommended the prohibition and additionally sought detailed reports from stakeholders on three specific antimicrobials before taking a final view on their inclusion in the ban.

Read Also: DTAB Recommends Ban on 34 Antimicrobials for Animal Use, Seeks Report on 3 Exceptions

Following antimicrobials and group of antimicrobials and their formulations for animal use: -

1. Antibiotics

i. Ureidopenicillins ii. Ceftobiprole iii. Ceftaroline iv. Siderophore cephalosporins v. Carbapenems vi. Penems vii. Monobactams viii. Glycopeptides ix. Lipopeptides x. Oxazolidinones xi. Fidaxomicin xii. Plazomicin xiii. Glycylcyclines xiv. Eravacycline xv. Omadacycline

2. Antivirals

i. Amantadine ii. Baloxavir marboxil iii. Celgosivir iv. Favipiravir v. Galidesivir vi. Lactimidomycin vii. Laninamivir viii. Methisazone/ Metisazone ix. Molnupiravir x. Nitazoxanide xi. Oseltamivir xii. Peramivir xiii. Ribavirin xiv. Rimantadine xv. Tizoxanide xvi. Triazavirin xvii. Umifenovir xviii. Zanamivir

3. Antiprotozoals

i. Nitazoxanide

Objections and suggestions can be submitted within 30 days of publication to the Under Secretary (Drugs), Ministry of Health and Family Welfare, either by post or by email at drugsdiv-mohfw@gov.in.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News